Inhibrx Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Inhibrx's earnings have been declining at an average annual rate of -37%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 37.9% per year.
Anahtar bilgiler
-37.0%
Kazanç büyüme oranı
-15.3%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | -37.9% |
| Özkaynak getirisi | -2,344.0% |
| Net Marj | -15,207.8% |
| Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?
May 13
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23Gelir ve Gider Dağılımı
Inhibrx nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -271 | 33 | 0 |
| 31 Dec 23 | 2 | -241 | 29 | 0 |
| 30 Sep 23 | 0 | -189 | 27 | 0 |
| 30 Jun 23 | 1 | -172 | 24 | 0 |
| 31 Mar 23 | 1 | -163 | 22 | 0 |
| 31 Dec 22 | 2 | -145 | 21 | 0 |
| 30 Sep 22 | 5 | -125 | 19 | 0 |
| 30 Jun 22 | 7 | -111 | 17 | 0 |
| 31 Mar 22 | 7 | -94 | 14 | 0 |
| 31 Dec 21 | 7 | -82 | 12 | 0 |
| 30 Sep 21 | 7 | -78 | 11 | 0 |
| 30 Jun 21 | 11 | -78 | 10 | 0 |
| 31 Mar 21 | 13 | -75 | 8 | 0 |
| 31 Dec 20 | 13 | -76 | 7 | 0 |
| 30 Sep 20 | 10 | -75 | 6 | 0 |
| 30 Jun 20 | 6 | -74 | 6 | 0 |
| 31 Mar 20 | 6 | -68 | 6 | 0 |
| 31 Dec 19 | 13 | -51 | 6 | 0 |
| 30 Sep 19 | 15 | -40 | 6 | 0 |
| 30 Jun 19 | 15 | -30 | 6 | 0 |
| 31 Mar 19 | 14 | -26 | 5 | 0 |
| 31 Dec 18 | 9 | -31 | 5 | 0 |
| 30 Sep 18 | 7 | -35 | 4 | 0 |
| 31 Dec 17 | 8 | -19 | 3 | 0 |
| 31 Dec 16 | 7 | -8 | 2 | 0 |
Kaliteli Kazançlar: INBX is currently unprofitable.
Büyüyen Kar Marjı: INBX is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: INBX is unprofitable, and losses have increased over the past 5 years at a rate of 37% per year.
Büyüme Hızlandırma: Unable to compare INBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: INBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Özkaynak Getirisi
Yüksek ROE: INBX has a negative Return on Equity (-2344.01%), as it is currently unprofitable.